COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

EMERALD FOUNDATION INC

NEW YORK, NY · EIN 133912580 · Form 990PF · FY2024 · NTEE T20J · Philanthropy & Grantmaking · Medium ($1M-$10M)
revenue
$1.4M
expenses
$968K
net assets
$25.3M
employees
profile · synthesized from sources

Private foundation based in New York that funds biomedical research focused on cancer, neurodegenerative diseases, and cellular metabolism. Awards grants to leading research institutions including MIT, Weill Cornell Medicine, and the Salk Institute. Focuses on early-stage, high-impact scientific investigations into disease mechanisms and therapeutic strategies.

named programs · 3 · from sources

What they call their work

Cancer Therapeutics Research
Supports studies on enhancing immunotherapies, targeted nanotherapies, and resistance mechanisms in cancers including breast, colorectal, and pancreatic cancer.
Cellular and Metabolic Mechanisms
Supports research on mitochondrial function, stress response pathways, microbiota interactions, and cell-environment dynamics in disease contexts.
Neurodegenerative Disease Research
Funds investigations into Alzheimer's disease pathologies and neuronal dysfunction, focusing on cellular mechanisms of cognitive decline and hyper-excitability.
activities · 4 groups

What they do

  • Cancer Research Funding 5 activities
    • Funding research on Treg lymphatic tumor migration and locally delivered targeted therapies
      Funds studies investigating the regulation of regulatory T cell (Treg) migration via lymphatic vessels and interactions with tumors and lymphatic endothelial cells to inform localized cancer treatments.
    • Funding research on ferroptosis-based strategies to enhance immunotherapy efficacy in breast cancer
      Funds scientific research exploring how ferroptosis-based approaches can improve the effectiveness of immunotherapies for breast cancer.
    • Funding research on lactate-induced suppression of NK cells in tumor environments
      Funds research to map transcriptional and protein changes induced by lactate in tumors and identify mechanisms by which natural killer (NK) cell function is suppressed.
    • Funding research on mitochondrial-derived vesicles in cancer cell metabolism
      Funds research using cell biology and genomics techniques to investigate the role of mitochondrial-derived vesicles in metabolic processes within cancer cells.
    • Funding research to improve targeted nanotherapies through enhanced nanoparticle accumulation
      Funds research aimed at increasing nanoparticle delivery to specific cell types to develop safer and more effective nanotherapies.
  • Genetic and Neurological Disease Research Funding 1 activity
    • Funding research on dendrite-centric Alzheimer's disease pathologies and neuronal dysfunction
      Funds studies examining cellular mechanisms linking Alzheimer’s-related dendritic pathologies to cognitive decline and neuronal hyper-excitability.
  • Medical Research Funding 1 activity
    • Funding research on maladaptive integrated stress response in human cardiomyocytes
      Funds research to understand how dysregulation of the integrated stress response affects heart cell function and whether pharmacological interventions can restore normal activity.
  • Uncategorized 3 activities
    • Funding research on lineage reversion mechanisms in resistance to WNT-targeted therapies for colorectal cancer
      Funds research to identify molecular regulators involved in lineage reversion that contribute to resistance against WNT-targeted treatments in colorectal cancer.
    • Funding research on microbiota-host genetic interactions affecting immunotherapy response in colorectal cancer
      Funds research to investigate how interactions between gut microbiota and host genetics influence responses to immunotherapy in colorectal cancer patients.
    • Funding research on survival mechanisms of anaerobic organisms under oxidative stress
      Funds studies to identify molecular mechanisms that allow anaerobic organisms to survive exposure to oxygen and oxidative stress conditions.
financials · form 990PF · fy2024
revenue
Total revenue$1.39M
Contributions & grants
Program service revenue
Investment income$1.10M79%
Other revenue$287K
expenses
Total expenses$968K
Program expenses
Admin / overhead
Fundraising
Salaries & benefits$125K
Grants paid out$1.55M
balance sheet
Total assets$25.35M
Cash
Investments
Liabilities
Net assets$25.35M
5 years on record · 2020–2024 · YoY revenue +34.9%
leadership · form 990 part vii · fy2024

Who runs it

paid leadership · 1
NameTitleHours/wkCompensation
JAMES P MAHAFFEY Vice President 40 $129K
board members · 3
  • ANDREW W HEYMANN — Pres/director
  • ERIKA KELLERHALS — Director
  • LUCA CANTELLI — Director
relationships · 9

Who they work with

  • DANA-FARBER CANCER INSTITUTE Partner — Funded research to map lactate-induced changes and identify mechanisms of NK cell suppression in tumor environments.
  • JOHN HOPKINS UNIVERSITY Partner — Funded research to investigate how colon microbiota and host genetics affect immunotherapy response in colorectal cancer.
  • MASSACHUSETTS INSTITUTE OF TECHNOLO Partner — Funded two research projects: one on ferroptosis-based enhancement of immunotherapies in breast cancer, and another on nanoparticle accumulation for targeted nanotherapies.
  • NYU SCHOOL OF MEDICINE Partner — Funded research to examine cellular mechanisms linking dendrite-centric Alzheimer's pathologies to cognitive dysfunction and hyper-excitability.
  • SALK INSTITUTE FOR BIOLOGICAL STUDI Partner — Funded research using cell biology and genomics to investigate mitochondrial-derived vesicles in cancer cell metabolism.
  • UNIVERSITY OF KENTUCKY Partner — Funded research to understand maladaptive changes in the integrated stress response pathway affecting heart cell function.
  • UNIVERSITY OF MARYLAND SCH OF MEDIC Partner — Funded two research projects investigating Treg lymphatic tumor migration and interactions to develop locally delivered targeted cancer therapies.
  • WEILL CORNELL MEDICINE Partner — Funded research to identify regulators of lineage reversion impacting resistance to WNT-targeted therapies in colorectal cancer.
  • WHITEHEAD INST FOR BIOMEDICAL RESEA Partner — Funded two research projects: one on molecular mechanisms of anaerobe survival under oxidative stress, and another on cell-surface proteins mediating PDAC cell microenvironment interactions.